Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions
Election of Dr. Alexandre LeBeaut and sa Riisberg as Independent Directors
Dividend of CHF 2.00 approved
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News:
At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented.
Shareholder approvals
Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd., as well as the consolidated Financial Statements of Vifor Pharma Group for 2020 by a large majority. The maximum possible 2022 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2020 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of the Board of Directors and the Executive Committee for the business year 2020. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders from 12 May 2021 on.
Dr. Alexandre LeBeaut and Åsa Riisberg elected to the Board
The Annual General Meeting confirmed Chairman Jacques Theurillat and the other members of the Board of Directors, Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, Dr. Sue Mahony and Kim Stratton in office.
Dr. Alexandre LeBeaut and Åsa Riisberg were elected as new members of the Board.
As previously announced, Dr. Gianni Zampieri and Gilbert Achermann did not to stand for re-election. The Board of Directors sincerely thanks them for their distinguished services for Vifor Pharma.
Remuneration Committee confirmed
Dr. Sue Mahony (Chairwoman), Prof. Dr. hon. Michel Burnier and Dr. Romeo Cerutti were re-elected to the Remuneration Committee for a term of one year.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
